Paper Details

  1. Home
  2. Paper Details

Benralizumab for <i>PDGFRA</i>-Negative Hypereosinophilic Syndrome.

Author: AlaoHawwa, BrownThomas, EllisJamie H, FayMichael P, GoldmanMitchell, KhouryPaneez, KlionAmy D, KolbeckRoland, KuangFei Li, KumarSheila, LeeNancy, LegrandFanny, MageeTamika, MakiyaMichelle, MaricIrina, NewboldPaul, PanchSandhya R, PiligianBrent, PowersAstin, QuezadoMartha, SunXiaoping, WareJeanAnne, WetzlerLauren, YanLi, YoonPryscilla

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., IntramuralFunding provided by the NIH for research projects within the NIH.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Benralizumab, a monoclonal antibody against interleukin-5 receptor alpha, was effective in reducing eosinophils and improving symptoms in patients with hypereosinophilic syndrome. More research is needed to determine long-term effectiveness and identify predictors of response.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Hypereosinophilic syndrome is a group of diseases defined by marked eosinophilia in blood or tissue and eosinophil-related clinical manifestations. Benralizumab is a monoclonal antibody against interleukin-5 receptor α, which is expressed on human eosinophils. METHODS: In this randomize...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/30943337

データ提供：米国国立医学図書館（NLM）

Benralizumab: A New Hope for PDGFRA-Negative Hypereosinophilic Syndrome

The management of [hypereosinophilic syndrome (HES)] is a challenging area, requiring tailored therapies based on individual patient characteristics. This study investigates the effectiveness of [benralizumab], a monoclonal antibody targeting [interleukin-5 receptor α], in patients with [PDGFRA-negative HES]. The researchers conducted a [randomized, double-blind, placebo-controlled, phase 2 trial] to assess the efficacy of benralizumab in a group of [symptomatic patients with PDGFRA-negative HES].

Benralizumab: A Promising Treatment for PDGFRA-Negative HES

The study found that benralizumab significantly improved the [primary endpoint] of [clinical response] in patients with PDGFRA-negative HES, compared to placebo. This suggests that benralizumab holds promise as a potential treatment for this challenging condition.

A New Era of Targeted Therapy for HES

This study provides further evidence for the effectiveness of [targeted therapies] in treating HES. The successful use of benralizumab, which specifically targets [interleukin-5 receptor α], highlights the potential of precision medicine approaches for addressing this complex condition.

Dr.Camel's Conclusion

The study's findings are as promising as a refreshing oasis in the desert. The researchers demonstrate the potential of [benralizumab] as a valuable treatment option for individuals with [PDGFRA-negative HES]. This study highlights the growing importance of [targeted therapies] in the fight against complex diseases, paving the way for personalized and effective treatments for patients.

Date :
  1. Date Completed 2019-04-19
  2. Date Revised 2020-02-25
Further Info :

Pubmed ID

30943337

DOI: Digital Object Identifier

NIHMS1529629

Related Literature

Article Analysis
・Effects of benralizumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.